Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
ViroMissile, Inc.
MacroGenics
Avacta Life Sciences Ltd
City of Hope Medical Center
University of Southern California
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Valo Therapeutics Oy
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
German Cancer Research Center
Shanghai PerHum Therapeutics Co., Ltd.
Xencor, Inc.
Prelude Therapeutics
DNAtrix, Inc.
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Prelude Therapeutics
Emory University
Tempest Therapeutics
Pfizer
Prelude Therapeutics
Quadriga Biosciences, Inc.
Genzada Pharmaceuticals USA, Inc.
Ludwig Institute for Cancer Research
Philogen S.p.A.
MacroGenics
Seagen Inc.
Celgene
Tocagen Inc.
National Institutes of Health Clinical Center (CC)
CytoMed Therapeutics Pte Ltd
Virginia Commonwealth University
Merrimack Pharmaceuticals
University Health Network, Toronto
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
Altor BioScience
Memorial Sloan Kettering Cancer Center
Duke University
The Cleveland Clinic
City of Hope Medical Center